Visiongain has launched a new pharma report ‘’Myasthenia Gravis (MG) Treatment Market Report 2020-2030’’ by Treatment (Medication, Surgery, HSCT), Diagnosis (Blood Tests, Electrodiagnostic, Edrophonium Test, Imaging), End User (Hospitals, Clinics, Academics), and Geography.

The global myasthenia gravis (MG) Treatment market is anticipated to grow at a lucrative CAGR of over 8% and anticipated to surpass USD 2.5 Billion by 2030.

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder thus causing weakness in the skeletal muscles. This rare disease is triggered by a failure of communication between nerve cells and muscles that causes problems in relaxing and contracting muscles controlling eyes and eyelids, talking, chewing, and facial expressions. According to the American Myasthenia Gravis Foundation, myasthenia gravis is the most prevalent form of a neuromuscular disorder. In the U.S., myasthenia gravis prevalence is about 14-20 instances per 100,000 individuals.

The worldwide market for myasthenia gravis is largely influenced by growing neuromuscular disorder incidences. Also, a growing number of clinical centers across the region and growing awareness of therapy are other variables that drive the development of the industry. However, the unfamiliarity with early symptoms, signs and expensive treatment-related costs are factors that would restrain the growth of the myasthenia gravis (MG) market.

The worldwide market for myasthenia gravis (MG) treatment is anticipated to show strong growth over the forecast period. The MG therapy market is driven by a strong pipeline of over 15 drug applicants, an enhanced focus on biological research and development, growing awareness, implementation of new therapies, favorable investment scenarios, growing health care facilities, and reimbursement strategies in developed economies. Also, it is anticipated that symptom-based therapies and emerging targeted therapies present significant market opportunities for market players in myasthenia gravis treatment industry.

North America holds the majority of market share owing to the growing number of drug manufacturing players and raising awareness about the long-term effects of myasthenia gravis. Moreover, growing government expenditure for the treatment of this disease in North America is fueling market growth. According to the National Centers for Advancing Translation Science (NCATS), in the U.S., around 1 in 500,000 people suffer from such disorders each year.

Asia Pacific is anticipated to grow with the highest CAGE over the forecast period owing to the growing awareness about neuromuscular disorders and improvement in healthcare facilities across countries such as Malaysia, Indonesia, India, and China.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global myasthenia gravis (mg) treatment market. Companies are also increasing their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as AbbVie Inc., Alexion Pharmaceutical Inc., Avadel Pharmaceuticals Plc, Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, CSL Behring, F. Hoffmann Roche La Ltd., GlaxoSmithKline plc, Grifols S.A., Novartis Pharmaceuticals Corporation, Pfizer, RPG Life Sciences, Shire Plc, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.